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ABSTRACT   
 
BACKGROUND: The prevalence of T2DM in Ethiopia is on the 
rise according to certain studies. Appropriate management 
approaches are required to achieve desired goals of therapy in the 
clinical setup. This study was conducted to assess the treatment 
pattern and the factors associated with BP and FPG control among 
patients with T2DM in Federal Police Referral Hospital.  
METHOD: An institution based cross sectional study was 
conducted from 15th October 2016 to 15th January 2017. A 
Systematic random sampling technique was employed in selecting 
the study participants. Data was collected using semi-structured 
interview and visiting medication records. SPSS version 20 was 
used for data analysis.  
RESULTS: Out of a total of 414 participants who fulfilled the 
inclusion criteria, 361 were successfully interviewed and 
considered for further analysis. Target BP level was achieved in 
206(57.1%) of the patients, whereas the proportion of hypertensive 
diabetics who attained the recommended BP target was 19.4% 
(n=40). Of the 361 participants who were checked about their 
current FPG level, only 142(39.3%) were found to be <130mg/dl. 
However, 87(24.1%) participants were found to control both BP 
and FPG levels. Gender, military status, comorbidity, type of 
therapy and dietary adherence showed a statistically significant 
association with outcome variables. 
CONCLUSION: The proportion of participants with T2DM who 
achieved target BP, FPG or both was suboptimal. A comprehensive 
approach that involves targeted education on self-management 
strategies, individualized treatment plans, and continuous 
evaluation of treatment outcomes should be practiced. 
KEYWORDS:  Blood pressure, Cross sectional study, Ethiopia, 




Diabetes mellitus (DM) is one of the leading non-communicable 
diseases affecting a growing number of the population worldwide. A 
pooled analysis of 751 studies by non-communicable disease (NCD) 
risk factor collaboration indicated that an estimated 422 million 
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adults were living with diabetes in 2014, 
compared to 108 million in 1980(1). In this study, 
the age standardized global prevalence of the 
disease nearly doubled since 1980, rising from 
4.7% to 8.5% in the adult population. A report by 
WHO has also documented that diabetes caused 
1.5 million deaths in 2012. And additional 2.2 
million deaths were also reported to occur as a 
result of increased risks of cardiovascular and 
other diseases. Forty-three percent of these 3.7 
million deaths occured before the age of 70 years 
majority being in low and middle income 
countires (2).  
Even though the burden of diabetes in 
Ethiopia is not clearly elucidated, there are few 
studies conducted in selected population groups 
which show a growing prevalence of the problem 
(3-6). It is also reported that diabetes is becoming 
one of the top two causes of admission to hospitals 
(7). According to a report of the International 
Diabetes Federation (IDF) in 2014, it was 
estimated that 4.9 million Ethiopians of the age 
group 20-79 lived with diabetes and more than 2.9 
million (26.9%) sufferred from impaired glucose 
tolerance (8). 
There is a direct relationship between 
development of DM related complications and 
poor control of glycemic, blood pressure and lipid 
level targets (2). Studies have reported that 
improved glycemic control can either  delay or 
prevent the occurrence of micro-vascular 
complications such as; diabetic retinopathy, 
nephropathy as well as disorders that would arise 
secondary to neuropathic attacks (9-10). 
Nevertheless, the risk of developing 
macrovascular (cardiovascular) complications is 
increased among patients with T2DM who have 
poor lipid, blood pressure, and in particular 
glycemic control (11).  
The American Diabetes Association (ADA) 
recommends that life style changes are the first 
line therapy for most individuals. However, the 
addition of metformin, other oral anti-diabetic 
drugs (OADs) and/ insulin is also warranted 
stepwise if the goals are not achieved with life 
style changes alone (11,12).  Even though a 
national diabetic guideline is not available in 
Ethiopia to set treatment targets, this study used 
the  blood pressure (BP) and fasting plasma 
glucose (FPG) target recommendations set in the 
ADA (11-14) and IDF (8) guidelines for T2DM 
adult outpatients  with either healthy or few 
comorbid status.  
This study was initiated to present and 
characterize treatment patterns of T2DM in the 
chronic care clinic of the study setting and, to 
estimate the proportion of patients who 
successfully have controlled both BP and FPG 
levels during their last visits of the study period. In 
addition, the factors associated with poor goal 
achievement in the pharmacotherapy of T2DM 
were determined. The study is deemed to 
contribute to the identification of appropriate areas 
of focus that would help in the achievement of 
target levels in BP and FPG management among 
T2DM patients.  
METHOD  
 
Study design and setting: An institution based 
cross sectional study was conducted in Federal 
Police Referral Hospital in Addis Ababa, Ethiopia, 
from 15th October 2016 to 15th January 2017. The 
hospital has a total of 300 beds and is engaged in 
providing both diagnostic and medical treatment 
services to closely 1900 in-patients and 22000 out-
patients. 
 
Source and study population: The source 
population of this study was all chronic patients 
who were attending to the outpatients of the 
hospital while the study population was the T2DM 
patients, and fulfilled the specified inclusion 
criteria. 
 
Inclusion and exclusion criteria: The inclusion 
criteria for the study comprised patients who had 
uninterrupted follow-up to the clinic since at least 
one year back, those with complete medical 
history in their chart or database records, those 
who had their last visit BP and FPG level status 
measured, those who were aged above 18 years, 
and those who gave informed verbal consent to 
participate in the study. On the other hand, T2DM 
patients with treatment duration of less than a 
year, those patients who had not been measured 
for their last visit BP and FPG levels, those with 
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incomplete records about their last visit 
measurement  (for patients who were either unable 
to recall or whose last visit records were 
unreadble), patients with incomplete medication or 
disease history either in the diabetes clinic or 
chronic care pharmacy database, and patients who 
did not give informed verbal consent were 
excluded from the study.  
 
Sample size: The sample size was calculated by 
using single population proportion formula (15) 
and the prevalence of diabetes mellitus among the 
members of Federal Police Commission who 
resided in Addis Ababa, the capital of Ethiopia 
(6).  
After adjusting the above figure using a finite 
population correction formula (15) to compute the 
minimum number of patients with T2DM and 
those who were on follow-up to the chronic care 
clinic, and adding a 10% non-response rate or 
incomplete records, the final sample size required 
for the study was 414.  
 
Sampling technique: A Systematic random 
sampling technique was employed in selecting the 
study participants. Initially, the total number of the 
study participants was identified based on their 
chronic care clinic visit and medication refill 
appointment dates in the chronic care pharmacy 
unit database. As refills were done every three 
months, the sampling interval was determined by 
dividing the total number of persons with T2DM 
to the required sample size. Accordingly, a 
random serial number between 0 and the sampling 
interval was selected, and selection was continued 
till the end based on the patient’s appointment date 
to refill the medications.  
 
Data collection procedure and quality 
assurance: Data was collected using semi-
structured interview of the study participants by a 
trained pharmacist. Interview was scheduled based 
on the participants’ refill date to the chronic care 
pharmacy unit. After obtaining their informed 
consent, participants were briefed about the 
purpose of the study, and invited whether they 
would want to participate in the study. They were 
also assured to withdraw from the interview at any 
moment if they were uncomfortable. Socio-
demographic characteristics, disease history and 
adherence issues were recorded by interviewing 
the participants. Last visit outcome results were 
taken from medication charts based on the 
medication record numbers (MRNs). Classes of 
drugs prescribed, type of therapy and number of 
drugs were identified from prescription papers and 
database records.   
For ensuring consistency, clarity and data 
quality, the interview was conducted in Amharic 
(the country’s official language which all 
participants speak). The data collector was trained 
for two days on the relevance of the study, data 
collection techniques, informed consent and 
confidentiality of the data collected. Prior to the 
start of the data collection, a pilot of 30 patients’ 
medication records obtained from the chronic care 
clinic was evaluated against the required variables 
in the study. Completeness of data was checked 
every day by principal investigators (PIs).  
 
Operational definitions  
 
Blood pressure control: Blood pressure was 
measured based on either the systolic or diastolic 
pressure records of the participant.  BP was 
assumed controlled if the systolic BP was between 
110 and 139 mmHg and diastolic BP was between 
70 and 89 mmHg. If either target was missed, it 
was considered that blood pressure was not 
controlled. 
 
Fasting plasma glucose control: Also used as 
glycemic control was considered between 100 and 
130mg/dl for this evaluation. 
Dietary adherence: This was measured based on 
vegetable, fiber, salt, fat and alcohol intake levels.  
Dietary adherence was considered good if the 
participant reported to taking at least 2 servings of 
vegetables/fruits for 3 or more days of the week, 
whole grains, fiber or fish at least 2 servings for 3 
or more days of the week, small amount of fat or 
sugar, less than 2.3g salt (<1Tea Spoon Full 
(TSF)) intake per day,  and less than 600ml 
alcoholic intake per day.  
 
Exercise adherence: This was considered active 
if the participant reported doing exercise for at 
least 30 minutes in 4 or more days of the week.  
 
Medication adherence: Medication adherence 
was measured based on a participant’s reported 
daily missed doses of the prescribed anti-diabetic 
medications. If the participant had not missed 
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more than 80 percent of the doses in a month, it 
was assumed to have a good adherence.  
Terminology: the terms ‘T2DM /patients’ and 
‘study/ participants’ have been used 
interchangeably in this article.    
 
Ethical approval and consent: The study was 
approved by the School of Pharmacy Research 
and Ethics Committee, College of Health 
Sciences, Addis Ababa University. Before the start 
of the actual data collection, permission was 
obtained from Federal Police Commission Health 
Service Directorate. The study was conducted 
with an informed verbal consent acquired from 
each participant, and the data collection was 
conducted confidentially. Personal identifiers such 
as medical record number (MRN), name, address 
and telephone number were not included in the 
personal information interview.  
 
Data analysis: The collected data was  coded and 
checked manually for completeness; it was entered 
into Statistical Package for Social Sciences (SPSS) 
version 20 and cleaned before analysis. Frequency 
distributions and percentage tables were used to 
present socio-demographic variables and 
participants’ characteristics. A multivariable 
logistic regression was performed to show 
possible associations between the dependent 
variables (BP, FPG and simultaneous BP and FPG 
targets) and independent (age, gender, and marital 
status, comorbidity, type of therapy, dietary 
adherence, medication adherence and physical 
exercise) variables.  Statistical significance was 
set at p < 0.05.  Target achievement of each 
outcome variable was tested individually and in 
combination.  Because national diabetes guideline 
was not available in Ethiopia, target levels used in 
this study were set based on recommendations by 
the ADA (11-14) and IDF (8). 
RESULTS  
Characteristics of study participants: Out of a 
total of 414 participants who fulfilled the inclusion 
criteria, 361 were interviewed successfully, and 
considered for further analysis which made a 
response rate of 87.2%.  The mean age of the 
respondents was 54.8 years with standard 
deviation (SD) of ±11.9 years. Duration of 
treatment ranged between 1 and 31 years with 
mean duration of 6.7 years. Systolic blood 
pressure ranged between 100 and 200 mmHg with 
mean of 131.6 and SD of ±16.7 mmHg. Diastolic 
blood pressure was reported between 60 and 120 
mmHg with mean of 84.7 and SD of ±9.0 mmHg. 
The mean (SD) of fasting plasma glucose level 
was 154 (±51) mg/dl ranging from 70 to 385 
mg/dl.  
More than half (56.5%) of the participants 
were males, while greater than 40% of the 
respondents were in the age group of below 45 
years. Nearly two-third (65.1%) of the participants 
in this study were members of the military while 
almost all (98.3%) were married.  About 
209(58%) of the participants had at least one type 
of comorbidity. The most frequent comorbidity 
was hypertension reported by 145(40.2%) of the 
participants followed by dyslipidemia (30.5%), 
cardiac abnormalities (2.2%), peripheral 
neuropathy (1.9%), dyspepsia (1.9%) and 
retroviral infection (1.4%).  
One hundred seventy-seven (49%) 
participants reported that they were taking oral 
combination therapy followed by those who 
reported Insulin and oral combination therapy 
(21.9%), and oral mono therapy (15%) (Table1). 
The oral combination therapies were metformin 
with glibenclamide. Metformin was also combined 
with long acting insulin suspension. The majority 
(94%) of the patients placed on the monotherapy 
regimen took metformin while the rest took either 
glibenclamide or glimepiride. The patients on the 
insulin combination therapy took both 
intermediate acting (NPH) and short acting 
(regular insulin) regimens or a mixed formulation 
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Table 1: Characteristics of T2DM patients attending the chronic care clinic of Federal Police Referral 
Hospital, 2017 (n=361) 
 




≤45 Years 150 41.5 
46-60 Years 127 35.2 
>60 Years 84 23.3 
    
Gender  
 
Female  157 43.5 
Male 204 56.5 
   
Military status 
 
Military  235 65.1 
Non-military 126 34.9 
   
Marital status Married  355 98.3 
Unmarried 6 1.7 
   
Comorbidity No  152 42.1 
Yes 209 57.9 
   
Type of therapy Oral mono therapy  54 15.0 
Oral combination therapy 177 49.0 
Insulin mono/combination  
therapy 
51 14.1 
Insulin+ Oral Combination 79 21.9 
                
Factors associated with blood pressure control: 
Overall, target BP level (both systolic and 
diastolic) was achieved in 206(57.1%) of the study 
participants, whereas the BP level reported by the 
rest of the participants was out of the 
recommended range. However, the proportion of 
hypertensive diabetics who attained the 
recommended BP target was 19.4% (n=40).  
The odds of achieving BP targets were 
analyzed in association to selected univariate and 
multivariate characteristics of T2DM patients. 
Accordingly, male gender (AOR: 0.26, 95% CI: 
0.13-0.53), being non-military (AOR: 0.35, 95% 
CI: 0.17-0.74 ), presence of comorbidity (AOR: 
0.16, 95%CI: 0.09-0.27), and being in the regimen 
of oral combination therapy (AOR: 0.42, 95%CI: 
0.20-0.88) showed  negative associations with BP 
target achievement (Table 2).   
Factors associated with fasting plasma glucose 
control: Out of the 361 participants who were 
checked about their current FPG level, only 142 
(39.3%) was found to be <130mg/dl which was 
regarded as good glycemic control. Out of the 
participant characteristics tested for potential 
association with target control of FPG, being non-
military in status (AOR: 0.73; 95% CI: 0.38-0.82), 
taking oral combination therapy (AOR:  0.37, 
95%CI: 0.18-0.76) and insulin +oral combination 
therapy (AOR: 0.33; 95% CI: 0.14-0.77) showed 
statistically significant negative associations. On 
the other hand, presence of comorbidity (AOR: 
1.8; 95% CI: 1.07-3.04) and good dietary 
adherence (AOR: 3.46; 95% CI: 2.04-5.87) 
showed high likelihood of FPG target achievement 
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Table 2: Multivariate association of selected characteristics with BP control among  T2DM patients in 
Federal Police Referral Hospital, Addis Ababa, 2017 (n=361) 
 
 
Characteristics   Target BP Control   COR (95%CI) AOR (95%CI) 
Yes (%)  No (%)  
 Age (Years) 
   
 
≤45  95(63.3) 55(36.7) 1.00 1.00 
46-60 71(55.9) 56(44.1) 0.73 (0.45-1.20) 0.66 (0.37-1.18) 
>60 40(47.6) 44(52.4) 0.53(0.31-0.91) 0.74 (0.36-1.52) 
      
Gender  
 
Female  108(68.8) 49(31.2) 1.00 1.00 
Male  98(48.0) 106(52.0) 0.42(0.27-0.65) 0.26(0.13-0.53)* 
      
Military status  
 
Military   130(55.3) 105(44.7) 1.00 1.00 
Non-military 76(60.3) 50(39.7) 1.23(0.79-1.91) 0.35(0.17-0.74)* 
      
Comorbidity  
 
No    122(80.3) 30(19.7) 1.00 1.00 
Yes    84(40.2) 125(59.8) 0.17(0.10-0.27) 0.16(0.09-0.27)* 




≤5 131(60.4) 86(39.6) 1.00 1.00 
6-10 43(52.4) 39(47.6) 0.72(0.43-1.23) 0.82(0.43-1.56) 
≥11 32(51.6) 30(48.4) 0.70(0.40-1.24) 0.83 (0.37-1.83) 
      






Oral mono therapy 35(64.8) 19(35.2) 1.00 1.00 
Oral combination 
therapy  
94(53.1) 83(46.9) 0.62(0.33-1.16) 0.42(0.20-0.88)* 
Insulin mono/combination 
therapy  
  30(58.8) 21(41.2) 0.78(0.35-1.71) 0.59(0.23-1.51) 
Insulin +oral 
combination therapy 
47(59.5) 32(40.5) 0.80(0.40-1.63) 1.16(0.50-2.68) 
      
Dietary 
adherence 
Poor 84(50.3) 83(49.7) 1.00 1.00 
Good  122(62.9) 72(37.1) 1.67(1.10-2.60) 1.63 (0.96-2.75) 
      
Physical 
exercise  
Inactive    22(48.9) 23(51.1) 1.00 1.00 
Active  184(58.2) 132(41.8) 1.46(0.78-2.73) 1.00(0.47-2.13) 
      
Medication 
Adherence 
Poor   19(41.3) 27(58.7) 1.00 1.00 
Good  187(59.4) 128(40.6) 2.10(1.12-3.90) 1.38(0.62-3.09) 
*statistically significant 
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Table 3: Multivariate association of selected characteristics with FPG control among  T2DM patients in 
Federal Police Referral Hospital, Addis Ababa, 2017 (n=361). 
 
 
Characteristics   Target FPG Control   COR (95%CI) AOR (95%CI) 















duration  (Years) 
 
 

















≤45  60(40.0) 90(60.0) 1.00 1.00  
46-60 43(33.9) 84(66.1) 0.77(0.47-1.26) 0.59(0.32-1.06) 
>60 39(46.4) 45(53.6) 1.30(0.76-2.23) 0.74(0.37-1.50) 
     
Female  57(36.3) 100(63.7) 1.00 1.00  
Male  85(41.7) 119(58.3) 1.25(0.82-1.92) 0.73(0.38-1.38) 
     
Military   105(44.7) 130(55.3) 1.00 1.00 
Non-military 37(29.4) 89(70.6) 0.52(0.32-0.82)* 0.42(0.21-0.82)* 
     
No  51(33.6) 101(66.4) 1.00  1.00 
Yes  91(43.5) 118(56.5) 1.53(0.99-2.36) 1.80(1.07-3.04)* 
     
≤5 82(37.8) 135(62.2) 1.00  1.00 
6-10 29(35.4) 53(64.6) 0.90(0.53-1.53) 1.04(0.54-1.98) 
≥11 31(50.0) 31(50.0) 1.65(0.93-2.91) 1.84(0.84-4.03) 
     
 Oral mono therapy 28(51.9) 26(48.1) 1.00 1.00  
 Oral combination 
therapy  




28(54.9) 23(45.1) 1.13(0.23-2.44) 0.70(0.29-1.70) 
Insulin +oral 
combination therapy 
27(34.2) 52(65.8) 0.48(0.24-0.98)* 0.33(0.14-0.77)* 
     
Poor   39(23.4) 128(76.6) 1.00  1.00 
Good   103(53.1) 91(46.9) 3.72(2.35-5.86)* 3.46(2.04-5.87)* 
     
Inactive   10(22.2) 35(77.8) 1.00 1.00  
Active   132(41.8) 184(58.2) 2.51(1.20-5.25)* 1.82(0.80-4.11) 
     
Poor   8(17.4) 38(82.6) 1.00 1.00  
 Good   134(42.5) 181(57.5) 3.52(1.59-7.78)* 2.08(0.82-5.25 
*statistically significant 
 
    
Factors associated with both blood pressure 
and fasting plasma glucose control: Overall, 
simultaneous BP and FPG level of only the 
87(24.1%) participants was found within the 
recommended range. The variables which showed 
statistically significant associations with control of 
the outcome variable were male gender 
(AOR:0.31; 95% CI: 0.15-0.66), being non-
military in status (AOR: 0.25; 95% CI: 0.11-0.55), 
taking oral combination therapy (AOR: 0.18; 95% 
CI: 0.08-0.40), taking insulin mono or 
combination therapy (AOR:  0.29; 95% CI: 0.11-
0.77), taking insulin+oral combination therapy 
(AOR: 0.32; 95%  CI: 0.13-0.81), and good 
dietary adherence (AOR: 5.68; 95% CI; 2.85-
11.35) (Table 4).  
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Table 4: Multivariate association of selected characteristics with both BP  and FPG control among T2DM 
patients in Federal Police Referral Hospital, Addis Ababa, 2017 (n=361). 
 
 
Characteristics   Target BP and FPG 
Control  
COR (95%CI) AOR (95%CI) 




≤45  42(28.8) 108(72.0) 1.00  1.00  
46-60 28(22.0) 99(78.0) 0.73(0.42-1.26) 0.53(0.26-1.05) 
>60 17(20.2) 67(79.8) 0.65(0.34-1.24) 0.52(0.22-1.22) 
      
Gender  
 
Female  46(29.3) 111(70.7) 1.00  1.00 
Male  41(20.1) 163(79.9) 0.61(0.37-0.99)* 0.31(0.15-0.66)* 
      
Military status  
 
Military   61(26.0) 174(74.0) 1.00 1.00 
Non-military 26(20.6) 100(79.4) 0.74(0.44-1.25) 0.25(0.11-0.55)* 
      
Comorbidity  
 
No  48(31.6) 104(68.4) 1.00 1.00 
Yes  39(18.7) 170(81.3) 0.50(0.31-0.81)* 0.59(0.32-1.09) 




≤5 60(27.6) 157(72.4) 1.00  1.00 
6-10 13(15.9) 69(84.1) 0.49(0.25-0.96)* 0.55(0.24-1.25) 
≥11 14(22.6) 48(77.4) 0.76(0.39-1.49) 0.96(0.38-2.42) 
 









     
Oral mono therapy 24(44.4) 30(55.6) 1.00  1.00  
Oral combination 
therapy  


















     
Poor  16(9.6) 151(90.4) 1.00 1.00 
Good   71(36.6) 123(63.4) 5.45(3.01-9.85)* 5.68(2.85-11.35)* 
     
Inactive   6(13.3) 39(86.7) 1.00  1.00 
Active  81(25.6) 235(74.4) 2.24(0.92-5.49) 1.32(0.46-3.82) 
     
Poor  4(8.7) 42(91.3) 1.00 1.00 




DM is a complex, chronic illness that requires 
continuous care targeting for reduction of multiple 
risk factors beyond glycemic control. Ongoing 
patient self-management education and support 
are critical to preventing acute complications and 
reducing their long-term progress of the disease 
(11-14). Particularly, achievement of 
hypertension, glycemic and lipid target levels 
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among T2DM patients is reported to result in 
halting such complications and improve quality of 
life (10, 16-18). In this study, a higher figure of 
BP control (both systolic and diastolic) was 
obtained.This might be attributed to the fact that 
majority of the participants were not hypertensive. 
However, the level of attaining target BP was 
found to vary significantly among  hypertensive 
and non-hypertensive subgroups. The proportion 
of hypertensive diabetics who achieved target BP 
level in this study was in line with findings from 
studies across developed nations which reported 
that only less than one-third of hypertensive 
diabetics achieved their target BP level (19,20). 
However, a higher figure(32.2%) was reported 
among a similar group of Korean patients to have 
reached their treatment goal (21). Even though the 
figure in our study appears to be lower (19.4%), 
the proportion of hypertensive diabetics is also 
relatively smaller (40.2% vs. 45%), whereas the 
total number of participants in the same study is 
higher (n=361) compared to the study in Korea 
(n=200). Nonetheless, this study indicates that the 
association between DM and hypertension is on 
the rise which might have led to the lower level 
BP target. Studies from Sweden and Spain have 
shown that diabetes and hypertension have 
additive interaction which, in turn, is linked to 
elevated renin-angiotensin-aldosterone system 
activity, hyper-insulinemia associated to increased 
renal reabsorption of sodium, and increased 
sympathetic tone (22, 23).  
In the present study, 142(39.3%) of the 
participants attained FPG of 130mg/dl or less 
which was classified as good glycemic level. 
Smaller figures of glycemic control level had been 
reported from Malaysia (24, 25) and Jordan (26). 
Reasons for the difference might include high 
proportion of patients with comorbidity and diets 
high in carbohydrates (24) and lack of physical 
activity in the respective countries (24,25) 
compared to ours. Conversely, a higher figure of 
good glycemic control level was documented by 
studies in Korea (21) and Japan (27). This could 
be because of higher literacy rate and availability 
of better treatment options in these countries.  
Simultaneous achievement of both BP and 
FPG, in the present study, was a remarkable 
challenge where only 24.1% of the participants 
were in the target range. However, even smaller 
figures of 14.8%, 11.2% and 18.8% were reported 
in Korea (21), Japan (27) and US (28) 
respectively. Even though more advanced 
management options are available in the 
developed nations, the fact that the present study 
considered only BP and FPG targets unlike the 
other studies (which in addition included lipid 
control) might have overestimated the figure. 
Variation in presence of cardiovascular diseases 
and other complications, diabetes self-
management approaches and genetic (racial) 
factors might have brought about the observed 
difference.   
Male gender was found to contribute to 
decreased glycemic control level in this study. 
This might be linked to the presence of various 
comorbid conditions among two-third of the male 
participants compared to the same case in females 
(46%). Many experimental and clinical studies 
have also evidenced that men are 
hemodynamically older than age matched pre-
menauposal women (29-31). Similarly, based on 
the two longitudinal studies; the FRAMINGHAM 
HEART STUDY (32) and the INTERHEART 
(33) studies, the overall median age for evident 
CVD is 10 years lower in men than in their female 
counterparts. The progress of many CVDs leads to 
more advanced complication and vascular 
dysfunction which, in turn, is related with visceral 
adiposity, insulin resistance (IR) and change in 
levels of various circulating factors (34). This 
variation is explained by many studies which have 
found that female hormone; especially, estrogen 
has a notable role in promoting cardiovascular 
protection (35-37), regulation of energy balance, 
fat distribution and insulin sensitivity (38). This 
also may imply that male gender and comorbidity 
had interactive effects in this association despite 
administration of anti-diabetic medications in both 
groups.  
Compared to oral mono-therapy, people who 
take any of the oral combination, insulin 
mono/combination or insulin+oral combination 
therapy were found to poorly control their BP and 
FPG targets. This may be attributed to multiple 
factors such as poor insulin self-administration 
(though the majority reported to have good 
medication adherence), presence of drug-drug or 
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drug-food interaction and insulin stability while 
stored at home.  
This study did not include cholesterol 
measures though this variable often plays a 
considerable role in glycemic control in addition 
to BP and FPG, as patient records were 
incomplete for the point of evaluation. Similarly,  
FPG was used an outcome variable since Hba1c 
tests were not available in the hospital. The  study, 
however, has tried to present an informative 
picture of T2DM treatment pattern and  associated 
factors  with achievement of BP and FPG targets  
and, may serve as a baseline for future studies.The 
proportion of participants with T2DM and those 
who achieved BP and FPG targets was suboptimal 
in the present study. Similarly, simultaneous 
achievement of both BP and FPG target levels was 
lacking in the three-fourth of the study 
participants. This implies that meeting targets in 
T2DM treatment needs a considerable attention 
though burden of the disease appears to be at its 
earlier stage of growth in the country. Gender, 
military status, comorbidity, type of therapy and 
dietary adherence showed statistically significant 
associations with BP and FPG level control. As 
T2DM is a complex effect of multiple risk factors, 
a comprehensive approach that involves targeted 
education on self-management strategies, 
individualized treatment plans and continuous 
evaluation of treatment outcomes should be 
practiced.  Further studies with better design and 
scope are also warranted to determine the 
magnitude of the problem, in the country, in a 
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